Doctoral School of Human and Veterinary Sciences, University of Bangui, Bangui, Central African Republic.
Department of Public Health, Faculty of Health Sciences, University of Bangui, Bangui, Central African Republic.
J Prev Med Public Health. 2024 Sep;57(5):490-498. doi: 10.3961/jpmph.24.280. Epub 2024 Aug 14.
The aim of this study was to identify factors associated with coverage in community-directed treatment with ivermectin for onchocerciasis control in savannah and forest areas in the Central African Republic.
A cross-sectional study was conducted in 2 districts where onchocerciasis is endemic. We employed a pretested and validated questionnaire that included questions about the socio-demographic characteristics of the respondents and variables relevant to coverage assessment. Multivariate logistic regression analyses were performed to identify the associations between surveyed mass drug administration (MDA) coverage and the variables considered, while accounting for potential confounding factors. A p-value <0.05 was considered statistically significant.
At the district level, the MDA program achieved a reach of 87.29% (95% confidence interval [CI], 86.03 to 88.55) in Bossangoa and 61.74% (95% CI, 59.56 to 63.92) in Kémo, compared to the reported rates of 90.02% and 91.70%, respectively. Women in both Bossangoa and Kémo were 1.28 times more likely to have taken ivermectin than men (95% CI, 1.12 to 1.47; p=0.008; 95% CI, 1.09 to 2.00; p=0.041, respectively). The age groups of 5-14, 15-24, and 25-34 were statistically associated with better distribution coverage in both districts. Individuals with knowledge of onchocerciasis were more likely to receive ivermectin compared to those without knowledge, with adjusted odds ratios of 1.41 (95% CI, 1.11 to 2.01; p=0.030) and 3.19 (95% CI, 2.91 to 4.08; p=0.001), respectively.
The authors recommend implementing measures to improve MDA coverage in future campaigns. These measures should include allocating sufficient time for MDA activities, providing health education, and mobilising the entire population.
本研究旨在确定中非共和国萨凡纳和森林地区社区定向治疗伊维菌素控制盘尾丝虫病覆盖范围相关因素。
在两个流行盘尾丝虫病的地区进行了横断面研究。我们使用了经过预测试和验证的问卷,其中包括关于受访者社会人口特征和与覆盖率评估相关变量的问题。进行了多变量逻辑回归分析,以确定在考虑潜在混杂因素的情况下,调查的大规模药物治疗(MDA)覆盖率与所考虑变量之间的关联。p 值 <0.05 被认为具有统计学意义。
在区一级,与报告的 90.02%和 91.70%相比,MDA 方案在博桑戈阿的覆盖率达到了 87.29%(95%置信区间 [CI],86.03 至 88.55),在凯莫的覆盖率达到了 61.74%(95% CI,59.56 至 63.92)。博桑戈阿和凯莫的女性服用伊维菌素的可能性是男性的 1.28 倍(95% CI,1.12 至 1.47;p=0.008;95% CI,1.09 至 2.00;p=0.041)。5-14 岁、15-24 岁和 25-34 岁年龄组在两个区的分布覆盖率方面均具有统计学意义。与不了解盘尾丝虫病的人相比,了解盘尾丝虫病的人更有可能接受伊维菌素治疗,调整后的优势比分别为 1.41(95% CI,1.11 至 2.01;p=0.030)和 3.19(95% CI,2.91 至 4.08;p=0.001)。
作者建议在未来的运动中采取措施提高 MDA 覆盖率。这些措施应包括为 MDA 活动分配足够的时间、提供健康教育和动员整个人口。